DP方案联合参芪扶正注射液治疗晚期非小细胞肺癌40例疗效评价

目的评价DP胡里奥方案联合参芪扶正注射液治疗Ⅲb-Ⅳ期非小细胞肺癌的临床疗效。方法将80例Ⅲb-Ⅳ期非小细胞肺癌患者随机均分为两组,各40例。治疗组予DP化学治疗（简称化疗）方案（多西他赛75 mg/m^2、第1天给药,顺铂25 mg/m^2静脉滴注、第1-3天给药,均静脉滴注）联合参芪扶正注射液（初始化疗第1天开始连续静脉滴注250 m L,滴注14 d后,间歇7 d,每21 d为1个周期）治疗,对照组单用DP化疗方案。至少2个周期后评价疗效、卡氏生活质量（KPS）评分改善情况及T淋巴细胞亚群（CD3^＋,CD4^＋,CD8^＋,CD4^＋/CD8^＋）和NK细胞比例。结果治疗组有效率（32.50%）较对照组（25.00%）高,但差异无统计学意义（P〉0.05）;治疗组KPS评分改善情况优于对照组（P〈0.05）;治疗组CD3^＋,CD4^＋,CD8^＋,CD4^＋/CD8^＋,NK细胞治疗前后比较差异无统计学意义,对照组除CD8^＋外均较治疗前下降,且治疗组治疗后各指标水平均显著高于对照组治疗后（P〈0.05）。结论 DP化疗方案联合参芪扶正注射液治疗Ⅲb-Ⅳ期非小细胞肺癌疗效较好,可使KPS评分得到改善并提高患者的免疫功能。

Effect Evaluation on DP Regimen Combined with Shenqifuzheng Injection in Treating 40 Cases of Non- Small Cell Lung Cancer

Objective To evaluate the clinical therapeutic effect of DP regimen combined with Shenqifuzheng Injection on Ⅲb- Ⅳ stage of non- small cell lung cancer（NSCLC）. Methods 80 patients with Ⅲb- Ⅳ stage of NSCLC were randomly divided into two groups,40 cases in each group. The treatment group was treated by the DP regimen,docetaxel 75 mg/m^2 by intravenous drip on 1 d and cisplatin 25 mg/m^2 by intravenous drip on 1- 3 d,which combined with Shenqifuzheng Injecfion 250 m L by intravenous drip for successive 14 d,then intermittent 7 d,with 21 d as a treatment cycle. The control group only received the DP regimen. After at least 2 cycles of treatment,the curative efficacy,improvement of the Karnofsky Performance Scale（KPS） scores,T lymphocyte subsets（CD3^＋,CD4^＋,CD8^＋,CD4^＋/CD8^＋）and NK cells proportion were evaluated in the two groups. Results The total effective rate after 2 cycles of treatment in the treatment group was 32. 50%,which was higher than 25. 00% in the control group,but the difference between the two groups had no statistical significance（P〉 0. 05）; the improvement situation of KPS scores in the treatment group was significantly better than that in the control group（P〈0. 05）; CD3^＋,CD4^＋,CD8^＋,CD4^＋/CD8^＋and NK cells in the treatment group had no statistical differences between before and after treatment（P 〉0. 05）,which except CD8^＋in the control group were decreased compared with before treatment,moreover the levels of various indexes after treatment in the treatment group were significantly higher than those in the control（P〈0. 05）. Conclusion The DP chemotherapy regimen combined with Shenqifuzheng Injection can achieve better efficacy for treating Ⅲb- Ⅳ stage of NSCLC,can improve the KPS scores and increase the immune function of patients.